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MicroRNAs (miRNAs) are a class of naturally occurring small 
non-coding RNAs of about 22 nucleotides that have recently 
emerged as important regulators of gene expression at the 
posttranscriptional level. Recent studies provided clear evi-
dence that microRNAs are abundant in the lung, liver and 
kidney and modulate a diverse spectrum of their functions. 
Moreover, a large number of studies have reported links be-
tween alterations of miRNA homeostasis and pathological 
conditions such as infectious diseases, sickle cell disease 
and endometrium diseases as well as lung, liver and kidney 
diseases. As a consequence of extensive participation of 
miRNAs in normal functions, alteration and/or abnormalities 
in miRNAs should have importance in human diseases. 
Beside their important roles in patterning and development,  
miRNAs also orchestrated responses to pathogen infections. 
Particularly, emerging evidence indicates that viruses use 
their own miRNAs to manipulate both cellular and viral gene 
expression. Furthermore, viral infection can exert a profound 
impact on the host cellular miRNA expression profile, and 
several RNA viruses have been reported to interact directly 
with cellular miRNAs and/or to use these miRNAs to aug-
ment their replication potential. Here I briefly summarize the 
newly discovered roles of miRNAs in various human diseases 
including infectious diseases, sickle cell disease and enod-
metrium diseases as well as lung, liver and kidney diseases.
[Immune Network 2011;11(6):309-323]
INTRODUCTION
miRNAs are found in almost all species: virus, plants, nemat-
odes, fly, fish, mouse, human, and are implicated in a wide 
array  of  cellular  and  developmental  process  (1).  There  are 
hundreds  of  miRNAs  encoded  in  the  human  genome  and 
thousands  of  target  mRNAs,  which  illustrates  the  important 
regulatory  roles  of  miRNAs  in  cell  development,  differen-
tiation, proliferation and apoptosis pathways (2,3). It is not 
surprising that deregulated miRNAs have been involved in the 
pathogenesis  of  many  human  disease  (4-10).  miRNAs  have 
recently emerged as important regulators of gene expression. 
They were formerly thought to mainly repress the translation 
of  target  mRNAs,  but  it  has  recently  been  shown  that  the 
main function of miRNAs in mammalian system is to decrease 
target mRNA levels (11). It is estimated that 20∼30 % of all 
human mRNA are miRNA targets (12). And so, it is probable 
that most mRNAs are controlled by miRNAs to some extent. 
The expression of miRNAs is highly regulated and they are 
therefore well placed to function as immunomodulators (13). 
More  recently,  miRNA  are  also  proving  to  be  an  important 
link between the innate and adaptive immune systems, and 
their dysregulation might have a role in the pathogenesis of 
various  diseases  (4-7,13,14).
    Importantly, it has been increasingly reported that miRNAs 
are associated with disease (4-6, 14-24). However, the pattern 
among  the  miRNA-disease  association  remains  largely  un-
clear. In order to dissect the patterns of miRNA-disease asso-MicroRNAs in Lung, Liver and Kidney Diseases and Infectious Diseases
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ciations, a study performed a comprehensive analysis to the 
human  miRNA  disease  association  data,  which  is  manually 
collected from publication (14). They built a human miRNA 
association  disease  network.  Interestingly,  miRNAs  tend  to 
show similar or different dysfunctional evidence for the sim-
ilar or different disease clusters, respectively (14). In addition, 
they also found that there is a negative correlation between 
the tissue-specificity of a miRNA and the number of disease 
it associated and that there is an association between miRNA 
conservation and disease (14). Furthermore, they uncovered 
that miRNAs associated with the same disease tend to emerge 
as predefined miRNA groups (14). The effect of inducing or 
repressing  miRNA  expression  can  influence  most  biological 
processes, including cell fate specification, cell proliferation, 
DNA  repair,  DNA  methylation  and  apoptosis  and  provide 
pro-inflammatory  or  anti-inflammatory  stimuli  (10,25).  Fur-
thermore,  with the  development of new techniques  for ge-
nome-wide screening of miRNA expression, abnormal levels 
of  miRNA  were  identified  in  various  diseases  with  respect 
with  normal  counterpart  (4-6,26,27).
    All miRNAs are processed and matured through a complex 
biogenesis  process  involving  multiple  protein  catalysis  ac-
cessory proteins, and macromolecular complexes following a 
coordinated  series  of  event  (28-30).  They  are  an  abundant 
class of gene regulatory molecules in multicellular organisms 
and modulate the expression of many protein-coding genes 
(28-30). They are transcribed as a huge double-stranded pri-
mary  transcript  (pri-miR)  by  RNA  polymerase  II.  Subse-
quently, nuclear enzyme Drosha and Pasha convert this pre-
cursor into a double-stranded miRNA precursor of ∼70 nul-
cleotide (pre-miR), which is next transported into the cyto-
plasm  by  a  mechanisms  involving  the  protein  Exportin  5 
(7,13,28,31). Finally, Dicer enzyme processes this precursor 
into the 22-nucleotide double-stranded miRNA. This duplex 
is  then  unwinded,  and  the  leading  strand  (“guide strand”), 
one of the two strands, is incorporated into the RNA-induced 
silencing complex (RISC), which is comprise Agonaute and 
other proteins (7,31,32). miRNAs incorporated in the RISC are 
able  to  bind  to  the  3'  untranslated  region  (UTR)  of  target 
mRNAs causing a block of translation or mRNA degradation 
depending on the level of complementarity (28,29). The other 
strand  so-called  “passenger  strand”  is  degraded  (7,28,33). 
Very importantly, miRNAS are altered or induced by both en-
vironmentally  regulated  early  life  developmental  factors 
through  epigenetic  and  miRNA  mechanisms,  and  genetic 
polymorphisms  including  protein  or  miRNA  genes  (34).
    Importantly, miRNA degradation may contribute to several 
pulmonary  disease  (15).  In  addition,  several  miRNAs  have 
been shown to be involved in pulmonary allergy and asthma 
and lung carcinogenesis (15). There are only few reports fo-
cused on the role of miRNAs in chronic obstructive pulmo-
nary disease (COPD), namely miR-146a is involved in COPD 
(16,17,35). Interestingly, changes in miRNA expression are an 
early event following exposure to cigarette smoke and bron-
chial airway epithelial cells from current and never smokers 
differ in the expression of 28 miRNAs in comparison to smok-
ers, whereas the majority of deregulated miRNAs are down 
regulated in smokers (36). Very interestingly, it has been re-
ported that many miRNAs may play pivotal role in homeo-
stasis  and  lung  development,  and  other  various  pulmonary 
diseases  such  as  idiopathic  pulmonary  fibrosis  (IPF)  (15, 
37-39) and cystic firbrosis (40). Recent studies provided clear 
evidence miRNAs are abundant in the liver and modulate a 
diverse spectrum of liver functions and that deregulation of 
miRNA expression may be a key pathogenic factor in many 
liver diseases including viral hepatitis, hepatocellular carcino-
ma  (HCC),  and  polycystic  liver  diseases  (19).  miR-122  is  a 
liver  specific  miRNA  (18).  Besides  miR-122,  many  other 
miRNAs  are  also  abundantly  expressed  in  adult  liver  tissue 
(19). Very recently, a large number of genes and signaling 
mechanisms have been implicated in ethanol’s deleterious ef-
fects leading to the suggestion that ethanol is a ‘dirty drug’ 
(41). It has been known that alcohol-induced gut leakiness 
is a key factor in alcoholic liver disease (ALD) and it allows 
endotoxin to enter the circulation and initiate liver damage 
and that ethanol increases miR-122 expression (42). It is now 
clear that key miRNAs are highly expressed in the kidney and 
can act as effector of TGF-βaction and high glucose in dia-
betic kidney disease (20). A striking increase in miR-214 was 
also detected in monocyte from patients with chronic renal 
failure and that miR-214 specifically binds to phosphatase and 
tensin homolog (PTEN) mRNA 3'UTR, implicating PTEN as a 
target gene of miR-214 (21). Numerous disorders are related 
to  cilia  dysfunction,  including  polycystic  kidney  disease 
(PKD), primary ciliary dyskinesia, nephrophthisis (43) Pandey 
et al. explored the possibility of miRNA-based regulations in 
PKD  (44).  The  authors  found  that  935  genes  were  differ-
entially  regulated  between P K D  a n d  h e a l t h y  c o n t r o l s .
    As mentioned, many viruses have been founded to encode 
miRNAs that regulate both viral and host mRNA (45). It has 
been shown that miRNAs encoded in the viral genome have 
the potential to reshape the cellular environment to maximize MicroRNAs in Lung, Liver and Kidney Diseases and Infectious Diseases
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viral replication (24,46) and viral miRNAs can suppress host 
cell genes involved in antiviral immunity (47). Interestingly, 
some viruses evade immune surveillance by targeting a cel-
lular  mRNA  with  a  virally  encoded  miRNA  and  viruses  use 
m i R N A s  n o t  o n l y  t o  r e g u l a t e  t h e i r  o w n  l i f e  c y c l e s  b u t  a l s o 
evade host immune surveillance (48). In contrast, the cellular 
miRNAs play an important role in the host, defending against 
virus  infection  (49).  As  for  bacterial  infections,  tuberculosis 
remains  a  major  health  issue,  causing  approximately  three 
million  deaths  every  year  (50).  Mycobacterium  tuberculosis 
remains one of the most enigmatic bacteria. Currently, Liu et 
al. performed miRNA expression profiling in peripheral blood 
mononuclear cells (PBMCs) from pulmonary tuberculosis pa-
tients and health controls (51). They showed that expression 
of  30  miRNAs  was  significantly  altered  during  active  tuber-
c u l o s i s  a s  c o m p a r e d  w i t h  h e a l t h y  c o n t r o l s  a n d  2 8  m i R N A s  
were up-regulated and 2 miRNAs down-regulated (51). They 
also showed that miR-144* was one of the miRNAs that were 
over-expressed  in  active  tuberculosis  patients.  Helocobacter 
pylori is the main cause of peptic ulceration and gastric ad-
enocarcinoma  in  human  (46,52).  H.  pylori w a s  a b l e  t o  i n-
crease miR-155 expression in gastric epithelial cell lines and 
gastric  mucosal  tissue  (46).  Currently,  a  study  showed  that 
H. pylori infections alter the expression of oncogenes, tumor 
suppressor genes and miRNAs (52). Surprisingly, Salmonella 
significantly induces several miRNAs and these miRNAs chief-
ly  induced  miR-155  and  miR-146a,  as  well  as  miR-21  (53). 
Treatment of immune cells with bacterial lipopolysaccharide 
(LPS)  from  Salmonella a n d  Escherichia  coli l e d  t o  t h e  i n -
duction  of  miR-155,  miR-132  and  miR-146  expression  (54).
    Since mature erythrocytes are terminally differentiated cells 
without  nuclei  and  organelles,  it  is  commonly  thought  that 
they do not contain nucleic acids (55). Interestingly, however, 
human  mature  erythrocytes  contains  diverse  and  abundant 
miRNAs (56). Increased expression of these miRNAs in pri-
mary erythroid progenitor cells results in elevated fetal and 
embryonic hemoglobin gene expression (57). Interestingly, it 
has been shown that during the menstrual cycle, human en-
dometrium undergoes extensive cyclic, morphologic and bio-
chemical modifications in preparation for embryo implanta-
tion and that endometrial expression of miRNAs and their po-
tential regulatory functions are under normal and pathologic 
conditions  such  as  endometeriosis,  dysfunctional  uterine 
bleeding,  and  endometrial  cancer  (58).
    miRNAs also have an essential role in both the innate and 
adaptive  immune  system.  Proper  miRNA  expression  is  re-
quired  for  correct  differentiation  of  immune  cells  (22).  Im-
mune responses are symphonies of molecular and cellular in-
teractions,  with  each  player  doing  its  part  to  produce  the 
composite behavior we see as effective host defense, or when 
discoordinated,  as  immunopatholgy  or  immunodeficiency 
(6,59). It is therefore not surprising that they have been im-
plicated in various human diseases, including lung diseases 
(15-17,35,60),  liver  diseases  (18,19,61-63),  kidney  diseases 
(20,21,43,44,64),  infectious  diseases  (22-24,61,65-69),  sickle 
cell disease (55-57), and endometrium disease (58,70). Here 
I briefly summarize the newly discovered roles of miRNAs in 
various  human diseases including infectious  diseases, sickle 
cell disease and enodmetrium diseases as well as lung, liver 
and  kidney  diseases.
miRNAs IN LUNG DISEASES
A recent study showed that miRNAs have a strong potential 
to regulate fundamental biological processes also in the lung 
compartment  and  at  least  900  different  miRNA  genes  have 
b e e n  d i s c o v e r e d  i n  t h e  h u m a n  g e n o m e  ( 1 5 ) .  A s  s h o w n  i n  
Fig. 1, the lung has a very specific miRNA expression profile. 
However,  the  knowledge  of  the  role  of  miRNAs  in  physi-
olgocial and pathological conditions in the lung is still limited. 
miRNA deregulation may contribute to several pulmonary dis-
eases (15). Interestingly, several miRNAs such as miR-148a/b, 
miR-152,  miR-21,  miR-126,  let-7,  miR-29a,  miR-  155  and 
miR-133a have been shown to be involved in pulmonary al-
lergy and asthma (15). And, several miRNAs such as miR-155, 
let-7, miR-17∼92 cluster, miR-212, miR-34 families, miR-210 
and miR-218 have been shown to be involved in lung carci-
nogenesis (15). There are only few reports focused on the role 
of miRNAs in chronic obstructive pulmonary disease (COPD): 
miR-146a is involved in COPD (16,17,35). COPD shares a com-
m o n  e n v i r o n m e n t a l  r i s k  f a c t o r  i n  c i g a r e t t e  s m o k e  e x p o s u r e 
(17). Recent studies on fibroblasts from COPD subjects stimu-
lated  in  vitro  with  pro-inflammatory  cytokines  released  less 
miR-146a  than  smokers  without  COPD  (35).  More  recently, 
a study demonstrated that eight miRNAs were expressed at 
a  significantly  lower  level  in  current-smoking  patients  with 
COPD  compared  with  never-smokers  without  airflow  limi-
tation and expression of let-7c and miR-125 was reduced in 
patients with COPD compare with healthy subjects and that 
target genes of let-7c were significantly enriched in the spu-
t u m  o f  p a t i e n t s  w i t h  s e v e r e  C O P D  ( 1 6 ) .  T h i s  s t u d y  a l s o  
showed  that  the  concentration  of  TNF  receptor  type  II MicroRNAs in Lung, Liver and Kidney Diseases and Infectious Diseases
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Figure 1. miRNAs involving in pathogenic processes in lung. There
is evidence that up-regulation or down-regulation of miRNAs is critical 
for the lung development and homeostasis and thus may contribute
to development of pathological pulmonary conditions, including lung
carcinogenesis, idiopathic pulmonary fibrosis, cystic fibrosis, chroinic 
obstructive pulmonary disease, smoking-related diseases and pulmo-
nary allergy and asthma (For the details, see Text).
(TNFR-II) was inversely correlated with the sputum levels of 
let-7c (16). This study indicated that let-7c is significantly re-
duced  in  the  sputum  of  currently  smoking  patients  with 
COPD and is associated with increased expression of TNFR-II. 
Interestingly,  Izzotti  et  al.  analyzed  the  expression  of  484 
miRNAs in the lungs of rats exposed to environmental ciga-
rette smoke (ECS) for 28 days and found that ECS down-regu-
lated 126 miRNAs (60). The most remarkably down-regulated 
miRNAs  belonged  to  the  families  of  let-7,  miR-10,  miR-26, 
miR-30, miR-34, miR-99, miR-122, miR-123, miR-124, miR-125, 
miR-140,  miR-145,  miR-146,  miR-191,  miR-192,  miR-219, 
miR-222, and miR-223, which regulate stress response, apop-
tosis,  proliferation,  angiogenesis,  and  expression  of  genes 
(60). In contrast, the authors also showed that miR-294, an 
inhibitor of transcriptional repressor genes, was up-regulated 
by ECS and that there was a strong paralleism in dysregula-
tion  of  rodent  miRNAs  and  their  human  homologues  (63). 
Importantly, the authors reported that changes in miRNA ex-
pression were an early event following exposure to cigarette 
smoke.  In  another  study,  bronchial  airway  epithelial  cells 
from current and never-smokers differed in the expression of 
28 miRNAs in comparison to smokers, whereas the majority 
of deregulated miRNAs were down-regulated in smokers (36). 
Furthermore, expression of miR-218 (a miRNA that is strongly 
affected by smoking) is reduced in primary bronchial eipthe-
lium exposed to cigarette smoke condensate (36). These data 
indicate  that  miR-218  levels  modulate  the  airway  epithelial 
gene  expression  response  to  cigarette  smoke.  Similar  ob-
servation  was  observed  in  lung  squamous  cell  carcinoma, 
where down-regulation of miR-218 was associted with a his-
tory  of  cigarette  smoking  (71).
    Very interestingly, it has been reported that many miRNAs 
may play pivotal role in homeostasis and lung development, 
and other various pulmonary diseases such as idiopathic pul-
monary fibrosis (IPF) (15,37-39) and cystic fibrosis (40). IPF 
is  a chronic,  progressive, and  usually  lethal  fibrotic  disease 
characterized by profound changes in epithelial cell pheno-
type  and  fibroblast  proliferation  (27,38,39). Recently, Liu  et 
al. showed that eighteen miRNAs including let-7d were sig-
nificantly decreased  in IPF and prevent  lung  fibrosis  which 
is a key regulatory role for this miRNA in IPF (38). They also 
demonstrated that TGF-β, a central pathologic mediator of 
fibrotic diseases, enhanced miR-21 expression in primary pul-
monary  fibroblasts  and  that  increasing  miR-21  levels  pro-
moted the pro-fibrogenic activity of TGF-β in fibroblast (38). 
The authors suggested an important role for miR-21 in fibrotic 
lung  diseases  and  also  suggested  a  novel  approach  using 
miRNA therapeutics in treating clinically refractory fibrotic dis-
eases  like  IPF.
    A  current  study  presented  evidence  that,  downstream  of 
TGF-β s i g n a l i n g ,  m i R N A s  o f  t h e  m i R - 2 3 a  c l u s t e r  a n d  t r a n-
scription factor Zeb1 could have roles in mediating an epi-
thelial to mesenchymal transition and the resultant persistence 
of mesenchymal cells in interstitial lung disease (72). Current-
ly,  as  shown  in  Fig.  1,  Pandit  et  al.  reported  that  approx-
imately 10% of the miRNAs are significantly changed in IPF 
lungs  (73).  They  also  showed  that  among  the  significantly 
down-regulated  miRNAs  are  member  of  let-7,  miR-29,  and 
miR-30  families  as  well  as  miR-17∼92  cluster  among  the 
up-regulated  miR-155  and  miR-21  and  that  down-regulation 
of let-7 family members leads to changes consistent with epi-
thelial cells both in vitro and in vivo, whereas inhibition of MicroRNAs in Lung, Liver and Kidney Diseases and Infectious Diseases
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miR-21 modulates fibrosis in the bleomycin model of lung fib-
rosis  (73).  A  recurrent  global  theme  is  that  many  miRNAs 
studied in IPF are both regulated by TGF-β1 and regulate 
TGF-β1  signaling  pathway  by  their  target  genes  (73).  The 
changes in miRNA expression in the IPF lung and the evi-
dence for their role in the fibrosis suggest that miRNA should 
be evaluated as therapeutic targets in IPF. It is interesting to 
note that acute interstitial pneumonia (AIP) clinically and ra-
diologically resemble IPF and is considered to represent the 
small subset of patients with idiopathic acute respiratory dis-
t r e s s  s y n d r o m e  ( A R D S )  a n d  i t  h a s  a  g r a v e  p r o g n o s i s  w i t h  
＞70%  mortality  in  3  months  (74).  It  is  synonymous  with 
Hamman-Rich  syndrome,  occurring  in  patients  without  pre- 
existing lung disease (74). As regards cystic fibrosis, cystic fib-
rosis is one of the most common lethal genetic diseases (40). 
A  recent  study  showed  miR-126  is  involved  in  this  disease 
and TOM1 mRNA is a miR-126 target that may have an im-
portant role in regulating innate immune response in the cyst-
ic  fibrosis  lung  (40).
miRNAs IN LIVER DISEASES
Recent studies have shown the involvement of miRNAs in te 
regulation of HCV infection (18,19,63). It has been reported 
that  miR-122  is  first  identified  liver-specific  cellular  miRNA 
and is specifically expressed and highly abundant in the hu-
man liver, which has been shown to enhance the replication 
of HCV by targeting the viral 5' non-coding region and that 
the sequestration of miR-122 in liver cells results in marked 
loss of autonomously replicating hepatitis C viral RNAs (18). 
It appears that HCV replication is associated with an increase 
in expression of cholesterol biosynthesis genes that are regu-
lated by miR-122 and hence is considered as potential target 
of antiviral intervention (65,75). Lecellier et al. also showed 
a cellular miRNA effectively restricts the accumulation of the 
retrovirus primate foamy virus type 1 (PFV-1) in human cells, 
indicating that cellular miRNAs have direct antiviral effects in 
addition to their regulatory functions (76). Therapeutic strat-
egies  based  on  modulation  of  miRNAs  activity  hold  great 
promise  due  to  the  ability  of  these  small  RNAs  to  potently 
influence cellular behavior. Kota et al. investigated the effi-
cacy of a miRNA replacement therapy for liver cancer (62). 
Interestingly, they found that HCC cells exhibits reduced ex-
pression of miR-26a, a miRNA that is normally expressed at 
high  levels  in  diverse  tissues  and  they  also  found  that  ex-
pression of this miRNA in liver cancer cells in vitro induces 
cell-cycle arrest associated with direct targeting of cyclins D2 
and E2 (62). In addition, the authors found that systemic ad-
ministration of this miRNA in a mouse model of HCC using 
adeno-associated virus results in inhibition of cancer cell pro-
liferation, induction of tumor-specific apoptosis, and dramatic 
protection  from  disease  progression  without  toxicity  (62). 
These findings provide a general strategy for miRNA replace-
ment therapies and proof-of-concept support for systemic de-
livery of tumor-suppressing miRNA as a powerful and highly 
specific anticancer therapeutic modality (62). As mentioned, 
it is now clear that miRNA can potentially regulate every as-
pect of cellular activity, including cellular differentiation and 
development, metabolism, proliferation, apoptotic cell death, 
v i r a l  i n f e c t i o n  a n d  t u m o r i g e n e s i s  ( 1 9 , 7 5 , 7 7 ) .  R e c e n t  s t u d i e s  
provided clear evidence that miRNAs are abundant in the liv-
e r  a n d  m o d u l a t e  a  d i v e r s e  s p e c t r u m  o f  l i v e r  f u n c t i o n s  a n d 
that deregulation of miRNA expression may be a key patho-
genic factor in many liver diseases including viral hepatitis, 
HCC and polycystic liver diseases (PCLDs) (19). As discussed, 
miR-122  is  a  liver  specific  miRNA  (18).  Besides  miR-122, 
m a n y  o t h e r  m i R N A s ,  s u c h  a s  m i R - 1 ,  m i R - 1 6 ,  m i R -  2 7 b ,  
miR-30d, miR-126, miR-133, mir-143, and the let-7 family, are 
also abundantly expressed in adult liver tissues (19). While 
miR-122 appears as the most highly expressed miRNA in adult 
liver, miR-92a and miR-483 seem to be more specifically ex-
pressed in the fetal liver (19). Thus, the liver displays a differ-
ential  miRNA  expression  profile  during  its  development. 
Recently, Chen reported that miRNAs are abundant and finely 
regulated in the liver and that miRNAs may be key players 
in the regulation of live functions (19). Furthermore, recent 
studies have shown the involvement of miRNAs in liver dis-
ease caused by various factors, such as HCV, HBV, metabolic 
disorders, and by drugs (19,63). Viral gene encodes miRNAs 
and these miRNAs have a regulatory effect on the viral pro-
tein-coding  genes  (75).  HBV  infection  is  a  global  problem 
and it can cause acute or chronic hepatitis B, liver cirrhosis, 
and, in some instances HCC (63). However, little is known 
about  the  involvement  of  miRNAs  during  HBV  infection. 
Considering the fact that cellular miRNAs play an important 
role in viral pathogenesis (61), it is likely that they have  a 
role in HBV infection. Using computational approach, HBV 
has been found to encode a candidate pre-miRNA, suggesting 
that HBV has the capacity to use viral miRNA to regulate its 
own gene expression (78). miRNA from the host cells may 
a l s o  p l a y  a  r o l e  i n  r e g u l a t i n g  v i r a l  g e n e s  ( 7 5 - 7 7 ) .
    Importantly,  Lee  et  al.  found  that  the  cholangiocyte  cell MicroRNAs in Lung, Liver and Kidney Diseases and Infectious Diseases
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line PCK-CCL, which is derived from the PCK rats, a model 
of  autosomal  recessive  polycystic  kidney  disease  (ARPKD), 
d i s p l a y e d  g l o b a l  c h a n g e s  i n  m i R N A  e x p r e s s i o n  c o m p a r e d  
with normal rat cholangiocytes (79). Interestingly, their more 
specific analysis revealed decreased levels of miR-15a, both 
in PCK-CLL cells and in liver tissue from PCK rats and patients 
with  PCLDs. They  also  found  that the  decrease  in  miR-15a 
expression was associated with up-regulation of its target, the 
cell-cycle  regulator  cell  division  cycle  25A (Cdc25A).  More-
over, they found that over-expression of miR-15a in PCK-CCL 
cells decreased Cdc25A levels, inhibited cell proliferation and 
reduced cyst growth (79). Furthermore, in contrast, they re-
ported  that  suppression  of  miR-15a  in  normal  rat  chol-
angiocytes  accelerated  cell  proliferation,  increased  Cdc25A 
expression,  and  promoted  cyst  growth  (210).  These  results 
suggest  that  suppression  of  miR-15a  contributes  to  hepatic 
cystogenesis  through  dysregulation  of  Cdc25A  (80).
    Drug-induced liver injury is a frequent side effect of many 
drugs  and  constitutes  a  significant  threat  to  patient  health. 
Numerous  efforts  have  been  made  to  identify  reliable  and 
predictive markers to detect the early signs of drug-induced 
injury  to  the  liver  (81).  Using  acetaminophen  overdose-in-
duced  liver  injury  in  the  mouse  as  a  model  system,  Wang 
et al. have observed highly significant differences in the spec-
trum and levels of miRNAs in both liver tissues and in plasma 
between  control  and  overdosed  animals  (81).  The  authors 
have also demonstrated that specific miRNA species, such as 
miR-122  and  miR-192,  both  are  enriched  in  the  liver  tissue 
and exhibit dose- and exposure duration-dependent changes 
in the plasma that parallel serum aminotransferase levels and 
the  histopathology  of  liver  degeneration,  but  their  changes 
can be detected significantly earlier (81). These findings sug-
gest that potential of using specific circulating miRNAs as sen-
s i t i v e  a n d  i n f o r m a t i v e  b i o m a r k e r s  f o r  d r u g - i n d u c e d  l i v e r  
injury.
  Very recently, a large number of genes and signaling mech-
anisms have been implicated in ethanol’s deleterious effects 
leading to the suggestion that ethanol is a “dirty drug” (41). 
Ethanol-sensitive  miRNAs  have  been  recently  identified  as 
master  switch  (41).  Accumulating  evidence  showed  that 
miRNAs  mediate  several  ethanol  pathologies,  including  dis-
ruption of neural stem cell proliferation and differentiation in 
the exposed fetus, gut leakiness that contributes to endotox-
emia and alcoholic liver disease, and possibly also HCC and 
other gastrointestinal cancer (41). It has been known that al-
cohol-induced gut leakiness is a key factor in alcoholic liver 
disease (ALD) and it allows endotoxin to enter the circulation 
and initiate liver damage and that Zonula occludens 1 (ZO-1) 
protein is a major component of tight junctions that regulates 
intestinal permeability (42). Tang et al. investigated the effect 
of alcohol on miR-212 and on expression of their target gene, 
ZO-1 (42). The authors found that ethanol increased miR-212 
expression, decreased ZO-1 levels, disrupted tight junctions, 
and increased the permeability of monolayerss of Caco-2 cells 
and that an miR-212 over-expression is correlated with hyper-
permeability of the monolayer barrier (42). In addition, they 
also found that miR-212 levels were higher in colon biopsy 
s a m p l e s  i n  p a t i e n t s  w i t h  A L D  t h a n  i n  h e a l t h y  c o n t r o l s  a n d  
ZO-1 protein levels were lower (42). These studies suggest 
a  novel  mechanisms  for alcohol-induced gut  leakiness, one 
in  which  ethanol  induces  miR-212  over-expression  which 
causes  gut  leakiness  by  down-regulating  ZO-1  translation. 
Alcoholic and nonalcoholic steatohepatitis are leading causes 
of liver diseases worldwide (41,82). While of different etiol-
ogy, these share common pathopysiological mechanisms and 
feature of abnormal fat metabolism, inflammation and fibrosis 
(41).  Dolganiuc  et  al.  reported  etiology-specific  changes  in 
miRNA  expression  profile  during  steatohepatitis  models, 
which opens new avenues for research in the pathophysiol-
ogy of alcoholic and nonalcoholic fatty liver disease (82). The 
authors reported that the both Lieber-DeCarli alcohol diet and 
methionine-choline-deficient  (MCD)  diets  lead  to  develop-
ment of liver steatosis, liver injury, indicated by increased ala-
nine  aminotrasnferase  (ALT),  and  elevated  levels  of  serum 
TNF, suggesting that animal models portray the pathophysi-
logical features of alcoholic and nonalcoholic fatty liver, re-
spectively  (82).  Interestingly,  the  authors  also  reported  that 
after 5 weeks of either diet, expression of both miR-705 and 
miR-1224 was increased, whereas expression of miR-182, and 
miR-199a was down-regulated during Lieber-DeCarli feeding 
and up-regulated during MCD feeding (82). They proposed 
that changes in miRNAs contribute to impaired hepatic lipid 
homeostasis and the inflammatory cascade in alcoholic steato-
hepatitis  and  nonalcoholic  steatohepatitis  (82).
miRNAs IN KIDNEY DISEASES
It is now clear that key miRNAs are highly expressed in the 
kidney and can act as effectors of TGF-β actions and high 
glucose in diabetic kidney disease (20). Moreover, it is inter-
esting that podocyte-specific deletion of Dicer, a key enzyme 
involved in miRNA biogenesis, led to proteinuria and severe MicroRNAs in Lung, Liver and Kidney Diseases and Infectious Diseases
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renal dysfunction in mice (20). Overwhelming evidence im-
plicating miRNAs in the pathology of key human diseases has 
sparked tremendous interest in development of modalities to 
block specific miRNAs and their function in vitro and in vivo 
(20). miRNAs, such as miR-192 and miR-377, may be novel 
targets  for  diabetic  nephropathy  and  other  diabetic  com-
plications.
    Advanced  glycation  end  products  (AGEs)  delay  sponta-
neous apoptosis of monocytes and continue to the develop-
ment of inflammatory response (21). Currently, a study inves-
tigated the role of miR-214 and its target gene in AGE-induced 
monocytic apoptosis delay (21). The authors reported that a 
striking increase in miR-214 was also detected in monocyte 
from patients with chronic renal failure and that miR-214 spe-
cifically  binds  to  phosphatase  and  tensin  homolog  (PTEN) 
mRNA 3'UTR, implicating PTEN as a target gene of miR-214. 
The study revealed also that PTEN expression is inversely cor-
related with miR-214 level in monocytes and that compared 
with normal monocytes, AGE-treated monocytes and mono-
cytes from chronic renal failure patients exhibited lower PTEN 
l e v e l s  a n d  d e l a y e d  a p o p t o s i s  ( 2 1 ) .
    Cilia  and  flagella  are  ancient,  evolutionary  conserved  or-
ganelles that project from cell surface to perform diverse bio-
logical roles, including whole-cell locomotion, movement of 
fluid,  chemosensation,  mechanosensation,  and  photosen-
sation, and sexual reproduction (64). Recently, the biological 
importance of primary cilia has been recognized in a number 
of human genetic diseases (43,64). Numerous disorders are 
related to cilia dynsfunction, including PKD, primary ciliary 
dyskinesia, nephronophthisis (43). Pandey et al. explored the 
possibility of miRNA-based regulations in PKD (44). The au-
thors  analyzed  the  simultaneous  expression  changes  of 
miRNAs  and  mRNAs  by  microarrays.  They  found  that  935 
genes,  classified  into  24  functional  categories,  were  differ-
entially regulated between PKD and control animals. In paral-
lel, 30 miRNAs were differentially regulated in PKD rats (44). 
Their results suggest that several miRNAS might be involved 
in regulating genetic switches in PKD. Furthermore, they de-
scribed  some  newly  detected  miRNAs,  miR-31  and  miR-217 
(44).  Their  results  suggest  an  important  role  of  miRNAs  in 
specific  pathways  underlying  PKD  (44).
miRNAs IN INFECTION
Emerging evidence suggest that miRNA-mediated gene regu-
l a t i o n  m a y  s e r v e  a s  a  d e f e n c e  m e c h a n i s m  a g a i n s t  v i r a l  i n -
fections in vertebrate cell (69). Pedersen et al. have shown 
that  the  IFN-signaling  system,  the  key  defence  mechanism 
against viral infection, works in concert with miRNAs to con-
trol viral infection (69). They have shown that IFN-β can in-
duce  the  expression  of  numerous  cellular  miRNAs.  Specifi-
cally,  eight  of  the  IFN-β-induced  miRNAS  (miR-1,  miR-30, 
miR-128, miR-196, miR-296, miR-351, miR-431 and miR-448) 
have  sequenced-predicted  targets  within  the  HCV  genomic 
RNA  (69).  In  addition,  they  demonstrated  that  IFN-βtreat-
ment leads to a significant reduction in the expression of the 
liver-specific miR-122, an miRNA that has shown to be essen-
tial for HCV replication (69). These findings strongly support 
the notion that mammalian organisms too, through the IFN 
system, use cellular miRNAs to combat viral infections (69). 
Several viruses, especially herpesviruses, also encode miRNAs 
and over 225 viral miRNAs have now been identified (83,84). 
Current evidence indicates that viruses use these miRNAs to 
manipulate  both  cellular  and  viral  gene  expression  (83,84). 
Furthermore, viral infection can exert a profound impact on 
the  cellular  miRNA  expression  profile,  and  several  RNA  vi-
ruses  have  been  reported  to  interact  directly  with  cellular 
miRNAs and/or to use these miRNAs to augment their repli-
cation potential. (83,84). Recently, some reports have shown 
that  a  limited  number  of  mammalian  miRNAs  are  also  in-
volved  in  anti-viral  defense  (83-86).
    Increasing  evidence  supports  that  miRNAs  also  have  im-
portant functions in viral replication and may be used by host 
cells to control viral infection (85). Expression of miRNAs has 
been reported for various groups of viruses including herpes-
viruses, small DNA viruses and retroviruses (85). The recent 
identification of target genes regulated by some of these viral 
miRNA suggests that they may function in the control of lytic 
and  latent  viral  replication,  in  the  limitation  of  antiviral  re-
sponses, in the inhibition of apoptosis, and in the stimulation 
of  cellular  growth  (85).  Importantly,  from  the  viral  perspe-
ctive, miRNAs encoded in the viral genome have the potential 
to reshape the cellular environment to maximize viral repli-
cation  (24,87).  In  this  context  they  have  several  potential 
advantages. Namely, they can specifically down-regulate host 
cell genes. They also occupy less than 200 nucleotides of the 
viral genome and are not antigenic (24). One can predict that 
viral miRNAs probably interfere with aspects of the host adap-
tive immune responses, including antigen presentation, or in-
nate immune responses, and the interferon system as shown 
i n  F i g .  2  ( 2 4 ) .  I t  i s  i n c r e a s i n g l y  c l e a r  t h a t  m i R N A s  o f  b o t h 
viral and cellular origin can positively or negatively influence MicroRNAs in Lung, Liver and Kidney Diseases and Infectious Diseases
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Figure 2. Possible functions of viral miRNAs. Many viruses have been
found to encode miRNAs that regulate both viral and host mRNA. 
miRNAs encoded in the viral genome have the potential to reshape
the cellular environment to maximize viral replication. miRNAs could
contribute to the maintenance and/or establishment of viral latent 
infection by protecting infected cells from undergoing apoptosis. 
miRNAs probably interfere with the host immune response, including
antigen presentation and the IFN system. Viral miRNAS can suppress
host cell gene involved in antiviral immunity and can control cell 
growth. IFN-β  production ("cytokine storm") can induce and/or 
modulate expression of numerous cellular miRNAs. Cellular miRNAs 
influence the replication of virus and antiviral activity may be 
mediated by IFN through cellular miRNAs.
viral  replication  (86).  Viral  miRNAs  can  directly  alter  host 
physiology, including component of the immune system, and 
host  miRNAs  can  directly  alter  the  virus  life  cycle  (86). 
Indeed, there is evidence that viral miRNAs can suppress host 
cell genes involved in antiviral immunity (47). For instance, 
a miRNA encoded in the genome of herpes simplex virus-1 
(HSV-1), miR-LAT, inhibits apoptosis by targeting TGF-β and 
SMAD-3, two components of the TGF-β pathway (47). Thus, 
viral miRNAs can maintain latent infections by protecting in-
fected cells from undergoing apoptosis. Viral miRNAs can al-
so  interfere  with  host  antiviral  responses  by  targeting  viral 
genes (87). Taken together, viral miRNAs may contribute to 
the  viral  immune  escape.
  Interestingly, Jopling et al. have shown that IFN-β also in-
duces the down-regulation of the expression of miR-122 (18). 
Not surprisingly, such a gene regulatory mechanism may also 
be exploited by virus to facilitate their infections (45). Many 
viruses have been founded to encode miRNAs that regulate 
both  viral  and  host  mRNA  (45).  Virus  that  encode  such 
m i R N A s  i n c l u d e  t h e  E p s t e i n - B a r r  v i r u s  ( E B V ) ,  c y t o m e g a l o -
viurs  (CMV)  and  Kaposi’s  sarcoma-associated  herpes  virus 
(88-90). Interestingly, a human cytomegaloviurs (HCMV)- en-
coded  miRNA,  miR-UL112,  repress  the  expression  of  MHC- 
class-1 polypeptide-related sequence-B (MICB) and MICB is 
a  stress-induced  ligand  of  the  NK-cell-activating  receptor 
NKG2D, which is required for NK-cell-mediated killing of vi-
rus-infected cells (47,48). Interestingly, these results demon-
strated that HCMV evades immune surveillance by targeting 
a cellular mRNA with a virally encode miRNA, and suggest 
that viruses use miRNAs not only regulate their own life cy-
cles but also evade host immune surveillance (48). It is inter-
esting to note that most viral miRNAs identified so far have 
no substantial homology to one another or to any known ani-
mal miRNAs and that miRNAs are only found in DNA viruses 
and  not  in  RNA  viruses  or  retroviruses  (89,91).
    In  order  to  investigate  the  global  and  dynamic  host 
miRNAs/mRNAs  expression  alteration  during  in  vitro a c u t e  
HCV infection, Liu et al. recently performed a comprehensive 
microarray  analysis  using  human  hepatoma  cell  (61).  They 
identified,  totally,  108  human  miRNAs  and  1247  mRNAs 
whose expression levels changed for more than 2.0-fold in 
response to HCV infection. They identified the differentially 
expressed  miRNAs  such  as  miR-24,  miR-149,  miR-638,  and 
miR-1181. In addition, the authors showed the miRNAs were 
involved  in  HCV  entry,  replication  and  propagation  (61). 
These results suggest that combined miRNA and mRNA profil-
ing may have superior potential as a diagnostic and mecha-
nistic feature in HCV infection. Ura et al. also reported that 
miRNAs are important mediators of HBV and HCV infection 
as  well  as  liver  disease  progression,  and  therefore  these 
miRNAs could be potential therapeutic target molecules (68). 
Importantly,  acute  retroviral  infection  provokes  rapid  and 
striking innate immune responses in what has been termed 
a cytokine storm and IFN-β production is an inaugural event 
in the innate immune response to viral infections (65). A re-
cent study showed that miRNAs, including miR-26a, miR-34a, 
miR-145, and let-7b, may directly regulate IFN-β in human 
and macaque cells and that in primary primate macrophages, 
the main cell type implicated in human immunodeficiency vi-
rus (HIV) and simian immunodeficiency virus infection in the 
CNS, specific miRNAs reduce, whereas miRNA inhibitors en-
hance,  IFN-β production  (65).MicroRNAs in Lung, Liver and Kidney Diseases and Infectious Diseases
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    The role of miRNAs in regulating gene expression has been 
increasingly appreciated in a wide spectrum of species includ-
ing plants, animals and viruses (22,50,76,92,93). It has been 
shown that miRNAs extensively mediate antiviral defenses in 
p l a n t s  a n d  a n i m a l s  ( 5 0 ) .  F o r  i n s t a n c e ,  h u m a n  m i R N A  h a s -  
miR-32 restricts the replication of retrovirus primate foamy vi-
rus  type  1  (PFV-1)  in  human  cells  (76).  Viruses  also  use 
miRNAs to regulate host cellular environment. For instance, 
miR-K12-11  encoded  by  Kaposi’s-sarcoma-associated  herpes 
virus down-regulates an extensive set of common host mRNAs 
(94). As already mentioned, a cellular miRNA effectively re-
stricts  the  accumulation  of  the  PFV-1  in  human  cell  and 
through  fortuitous  recognition  of  foreign  nucleic  acids,  cel-
lular miRNAs have direct antiviral effects in addition to their 
regulatory  functions  (76).  More  interestingly,  the  latency  of 
H I V  t y p e  1  ( H I V - 1 )  i n  r e s t i n g  p r i m a r y  C D 4＋T  cells  is  the 
major barrier for the eradication of the virus in patients on 
suppressive highly active antiretroviral therapy (HAART) (95). 
Even with optimal HAART, replication-competent HIV-1 still 
exists in resting primary CD4＋ T cells. Huang et al. demon-
strated that cellular miRNAs potently inhibit HIV-1 production 
in resting primary CD4＋ T cells (95). Interestingly, they have 
found that the 3' ends of HIV-1 mRNAs are targeted by a clus-
ter of cellular miRNAs including miR-28, miR-125b, miR-150, 
miR-223 and miR-382, which are enriched in resting CD4＋ 
T cells as compared to activated CD4＋ T cells (95). Their 
data indicate that cellular miRNAs are pivotal in HIV-1 latency 
and  suggest  that  manipulation  of  cellular  miRNAs  could  be 
a novel approach for purging the HIV-1 reservoir (95). In ad-
dition to HIV, the H1N1 influenza virus continue to pose seri-
ous threat to public health. Recently, Song et al. reported that 
miR-323, miR-491 and miR-654 inhibit replication of the H1N1 
influenza  A  virus  through  binding  to  the  PB1  gene  (49). 
Intriguingly, despite the fact that the miRNAs and PB1 mRNA 
b i n d i n g  s e q u e n c e s  a r e  n o t  a  p e r f e c t  m a t c h ,  t h e  m i R N A s  
down-regulate PB1 expression through mRNA degradation in-
stead  of  translation  repression  (49).  This  may  be  the  first 
demonstration  that  cellular  miRNAs  regulate  influenza  viral 
replication by degradation of the viral gene. These findings 
support the notion that any miRNA has antiviral potential, in-
dependent  of  its  cellular  function,  and  that  the  cellular 
miRNAs play an important role in the host, defending against 
virus  infection  (49).  To  determine  whether  differential  ex-
pression of cellular miRNAs plays a role in the host response 
to  the  reconstructed  1918  influenza  virus  (r1918),  Li  et  al. 
compared the lung cellular “microRNAome” of mice infected 
by r1918 virus with that of mice infected by a nonlethal sea-
sonal influenza virus, A/Texas/36/91 (23). The authors found 
that  a  group  of  miRNA,  including  miR-200a  and  miR-223, 
were  differentially  expressed  in  response  to  influenza  virus 
infection and that r1918 and A/Texas/36/91 infection induced 
distinct miRNAs expression profiles (23). Moreover, they ob-
served significant enrichement in the number of predicted cel-
lular target mRNAs whose expression was inversley correlated 
with the expression of these miRNAs (23). Interestingly, gene 
o n t o l o g y  a n a l y s i s  r e v e a l e d  t h a t  m a n y  o f  t h e s e  m R N A s  p l a y 
roles in immune response and cell death pathway, which are 
known to be associated the extreme virulence of r1918 (23). 
These data strongly suggested that cellular gene expression 
patterns in influenza virus-infected mice may be attributed to 
miRNA  regulation  and  that  such  regulation  may  be  a  con-
tributing  factor  to  the  extreme  virulence  of  the  r1918  (23). 
More recently, Zhang et al. reported suppression of HBV rep-
lication by miR-199a-3p and miR-210 (67). It is interesting to 
note that accumulating evidence suggest that miRNA control 
the replication of both RNA and DNA virus (67). Currently, 
Potenza et al. reported that the analysis of the HBV genome 
by  computer  program  MiRanda  led  to  the  identification  of 
seven sites that are potential targets for human liver miRNAs 
(96). These site were found to be clustered in a 995-bp seg-
ment within the  viral polymerase ORF  and the  overlapping 
s u r f a c e  a n t i g e n  O R F ,  a n d  c o n s e r v e d  a m o n g  t h e  m o s t  c o m-
mon  HBV  subtypes.  One  of  the  selected  miRNAs,  has- 
miR-125a-5p, was found to interact with the viral sequence 
and to suppress the reporter activity markedly (96). Interest-
ingly, the miRNA was then shown to interfere with the viral 
translation, down-regulating the expression of the surface an-
tigen (96). Overall, these results support the emerging con-
cept that some mammalian miRNAs play a role in virus-host 
interaction. Furthrmore, the authors provided the basis for the 
development of new strategies for anti-HBV intervention (96).
    Transmissible spongiform encephalopathies (TSEs) or prion 
disease, are an invariably fatal class of neurodegeneartive dis-
orders  (97).  However,  little  is  known  about  their  role  of 
miRNAs  in  neurodegeneration.  Using  microarrays  and  RT- 
PCR,  Saba  et  al.  investigated  profile  of  miRNA  expression 
changes in the brains of mice infected with mouse-adapted 
scrapie (97). The authors found that 15 miRNA were deregu-
lated during the disease process; miR-342-3p, miR-320, let-7b, 
miR-328, miR-128, miR-139-5p, and miR-146a were over 2.5 
fold up-regulated and miR-338-3p, and miR-337-3p over 2.5 
fold  down-regulated  (97).  Only  one  of  these  miRNAs, MicroRNAs in Lung, Liver and Kidney Diseases and Infectious Diseases
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miR-128,  has  been  shown  to  be  deregulated  in  neuro-
degenerative disease. Taken together, they presented the first 
comprehensive  analysis  of  miRNA  expression  in  the  brain 
during  prion-induced  neurodegeneration  and  reported  that 
differential expression of 15 miRNAs, majority of which are 
up-  regulated  during  prion  disease  (97).
    As  for  bacterial  infections,  tuberculosis  remains  a  major 
health issue, causing approximately three million deaths every 
year (50). Mycobacterium tuberculosis, the causative agent for 
tuberculosis, remains one of the most enigmatic bacteria. The 
interactions  between  M.  tuberculosis  and  its  environment 
have  been  extensively  studied.  However,  our  knowledge 
about  potential  M.  tuberculosis-host  interaction  at  the  RNA 
level  is  still  very  limited.  Guo  et  al.  presented  finding  that 
suggests possible interactions of human miRNAs with M. tu-
berculosis transcripts and speculated possible roles of human 
miRNAs in regulating macrophage-M. tuberculosis interactions 
(50). Using an miRNA target prediction software miRanda fol-
lowed by analyses of cross-species conservation and miRNA 
expression  profile,  they  predicted  26  candidate  M.  tuber-
culosis  genes  that  may  be  targeted  by  human  miRNAs  ex-
pressed in the lung or macrophages, including genes related 
to  M.  tuberculosis  drug  resistance,  virulence  and  growth 
(50,92).  Central  to  the  pathogenic  virulence  of  M.  tuber-
culosis  is  its  ability  to  persist  and  multiply  within  alveolar 
macrophages after being phagocytosed, forming the primary 
lesion or tubercle (50,92). Currently, to understand whether 
miRNAs play roles in regulating immune responses to M. tu-
berculosis infection in humans, Liu et al. performed miRNA 
expression profiling in PBMCs from patients with pulmonary 
tuberculosis and health controls (51). They showed that ex-
pression of 30 miRNAs was significantly altered during active 
tuberculosis  as  compared  with  healthy  controls  and  28 
miRNAs  were  up-regulated  and  2  miRNAs  down-regulated. 
They also showed that miR-144* was one of the miRNAs that 
were overexpressed in active tuberculosis patients. Interest-
i n g l y ,  r e a l - t i m e  R T - P C R  a n a l y s i s  s h o w e d  t h a t  m i R - 1 4 4 *  w a s  
mainly expressed in T cells (51). Additionally, transfection of 
T cells with miR-144* precursor demonstrated that miR-144* 
could inhibit TNF-α and IFN-γ production and T cell pro-
liferation (51). They concluded that miR-144* might involve 
in  regulation  of  anti-tuberculosis  immunity  through  mod-
ification  of  cytokine  production  and  cell  proliferation  of  T 
cells. As for another bacteria, Helicobacter pylori is a Gram- 
negative  microaerophilic  bacterium  estimated  to  colonize 
more than half the world's population (46,98). It typically es-
tablishes a life-long infection with the stomach, where it in-
duces  a  marked  immune  response  with  local  infiltration  of 
neutrophil, lymphocytes and macrophages (46,98). H. pylori 
is  the  main  cause  of  peptic  ulceration  and  gastric  adeno-
carcinoma and it has been shown to cause B cell mucosa as-
sociated  lymphoid  tissue  lymphoma,  while  several  mecha-
nisms involved in adenocarcinoma induction have been de-
scribed, mechanisms underlying the onset of other H. pylo-
ri-implicated lymphomas remain obscured (46,98). Currently, 
a study showed that H. pylori infections alter the expression 
of  oncogenes,  tumor  suppressor  genes  and  miRNAs  (52). 
Xiao et al. reported that H. pylori was able to increase the 
miR-155 expression in gastric epithelial cell lines and gastric 
mucosal tissues, and nuclear factor-κB (NF-κB) and activa-
tor  protein-1  pathway  were  required  for  the  induction  of 
miR-155 (46). They also found that miR-155 may down-regu-
late IκB kinase ε, Sma- and Mad-related protein (SMAD2), 
and  Fas-associated  death  domain  (FADD)  protein.  Further-
more, the authors showed that the over-expression of miR- 
155  negatively  regulated  the  release  of  IL-8  and  growth-re-
lated oncogene-α (46). This study may provide the first de-
scription of increased expression of miR-155 in H. pylori in-
fection, and miR-155 may function as novel negative regulator 
that  help  to  fine-tuning  the  inflammation  of  H.  pylori i n -
fection (46). Interestingly, Belair et al. reported that miR-21 
was also over-expressed in chronically H. pylori-infected gas-
tric epithelium tissue, as opposed to noninfected tissue (66). 
Recently, Fehri et al showed that miR-155 is induced by H. 
pylori ( 9 8 ) .  C u r r e n t l y ,  M a t s u s h i m a  e t  a l .  d e t e r m i n e d  e x -
pression pattern of miRNAs in gastric mucosa infected with 
H. pylori (99). Using endoscopic biopsy specimens, the au-
thors determined miRNA expression patterns in H. pylori-in-
fected  gastric  mucosa  by  microarray  (99).  They  quantitated 
the differentially expressed miRNAS by real-time RT-PCR. An 
in  vitro i n f e c t i o n  m o d e l  w a s  a s s e s s e d  t o  m o n i t o r  t h e  r e g u-
lation  of  miRNAs  in  gastric  epitherlium  in  response  to  H. 
pylori. The comprehensive method unraveled the expression 
profile. Namely, among 470 human miRNAs loaded, 55 were 
differentially expressed between H. pylori-positive and -nega-
tive subjects. They showed that expression levels were sig-
nificantly decreased  in  30  miRNAs,  whereas  hsa-miRNA-223 
was  the  only  miRNA  to  be  overexpressed  on  quantitative 
RT-PCR and that eight miRNAs enabled discrimination of H. 
pylori  status  with  acceptable  accuracy.  They  reported  that 
gastritis scores of activity and chronic inflammation according 
to the updated Sydney system correlated significantly with the MicroRNAs in Lung, Liver and Kidney Diseases and Infectious Diseases
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expression levels of diverse miRNAs (99). Interestingly, they 
showed that cure of the infection with an anti-H. pylori regi-
men restored decreased expression of 14 of the 30 miRNAs 
and  that expression levels of  some miRNAs,  including let-7 
family members, were significantly altered following infection 
with a virulent H. pylori strain carrying intact cag pathoge-
nicity  island  including  cagA  but  not  isogenic  mutant  (99). 
These results may provide insight into miRNA involvement in 
the  pathogenesis  of  H.  pylori-associated  gastritis.
  A s  r e g a r d s  Salmonella  infection,  Tili  et  al.  showed  treat-
ment of immune cells with bacterial lipopolysaccharide (LPS) 
from Salmonella and Escherichia coli led to the induction of 
miR-155,  miR-132  and  miR-146a  expression  (54).  Most  re-
cently,  Schulte  et  al.  investigated  the  role  of  miRNAs  in 
mounting defences against such an intracellular bacteria, us-
ing mouse and human in vitro systems that recapitulate in-
fection  by  Salmonella  enterica,  the  agent  of  gastroenteritis 
(53). Deep sequencing revealed that Salmonella significantly 
induces several miRNAs within 4 h of mouse macrophage in-
fection (53). Perhaps not surprisingly, these miRNAs chiefly 
induced  miR-155  and  miR-146a,  as  well  as  miR-21  (53). 
Strikingly, several members of the let-7 miRNA gene family 
were, by contrast, rapidly down-regulated. Mutant Salmonella 
defective in cell invasion and/or intracellular replication also 
triggered  let-7  down-regulation,  suggesting  that  the  process 
involves sensing of extracellular bacterial antigen (53). This 
study identifies the let-7 family as the common denominator 
of  Salmonella-regulated  miRNAs  in  macrophages  and  epi-
thelial cell, and suggests that repression of let-7 relieves cyto-
kine IL-6 and IL-10 mRNAs from negative post-transcriptional 
control.  Intriguingly,  while  IL-6  is  pro-inflammatory,  IL-10 
p r e v e n t s  t h e  d e t r i m e n t a l  c o n s e q u e n c e s  o f  s y s t e m i c  i n f l a m -
mation, suggesting that the observed response is tightly bal-
anced and hence biologically relevant (100). These results es-
tablish  a  paradigm  of  miRNA-mediated  feed-forward  activa-
tion of inflammatory factors when mammalian cells are tar-
geted  by  bacterial  pathogens  (53).
miRNAs IN SICKLE CELL DISEASE (SCD)
Since  mature  erythrocytes  are  terminally  differentiated  cells 
without  nuclei  and  organelles,  it  is  commonly  thought  that 
t h e y  d o  n o t  c o n t a i n  n u c l e i c  a c i d s  ( 5 5 ) .  C h e n  e t  a l .  i n v e s -
tigated this issue by analyzing the transcriptome of a purified 
population  of  human  mature  erythrocytes  from  individuals 
with normal hemoglobin (HbAA) and homozygous sickle cell 
disease (HbSS) (56). They found a dramatic difference in their 
miRNA  expression  pattern  and  also  reported  that  miR-320 
played an important role for the down-regulation of its target 
gene, CD71 during reticulocyte terminal differentiation (56). 
Importantly, they also provided several lines of evidence that 
human  mature  erythrocytes,  although  lacking  in  ribosomal 
and large-sized RNAs, contain diverse and abundant miRNAs 
(56).  Further  investigation  revealed  that  poor  expression  of 
miR-320  in  HbSS  cells  was  associated  with  their  defective 
down-regulation  CD71  during  terminal  differentiation  (56). 
Thus, the global analysis of miRNA expression in circulating 
erythrocytes can provide mechanistic insights into the disease 
phenotypes  of  erythrocyte  disease.
    In human trisomy 13, there is delayed switching and persis-
tence of fetal hemoglobin (HbF) and elevation of embryonic 
hemoglobin in newborns. Currently, using partial trisomy cas-
es, Sankaran et al. mapped this trait to chromosomal band 
13q14; by examining the genes in this region, two miRNAs, 
miR-15a and miR-16-1, appear as top candidates for the ele-
vated HbF levels (57). Indeed, increased expression of these 
miRNAs in primary human erythroid progenitor cells results 
in elevated fetal and embryonic hemoglobin gene expression 
(57).  Moreover,  they  showed  that  direct  target  of  these 
miRNA, MYB, plays an important role in silencing the fetal 
and embryonic hemoglobin genes (56). These data suggest 
that  miR-15a,  miR-16-1,  and  MYB  may  be  important  ther-
apeutic targets to increase HbF levels in patients with sickle 
cell  disease  and  β-thalassemia  (57).
miRNAs IN ENDOMETRIUM DISEASES
During the menstrual cycle, human endometrium undergoes 
extensive cyclic, morphologic and biochemical modifications 
in preparation for embryo implantation that are remarkably 
consistent  during  each  cycle  throughout  the  reproductive 
years (58). This process, which begins with degenerative sig-
nals  resulting  in  menstrual  bleeding  and  endometrial  shed-
ding, integrates many overlapping and dynamic events to re-
generate and become receptive (58). Pan and Chegini et al. 
provided  evidence  showing  the  endometrial  expression  of 
miRNAs and their potential regulatory functions under normal 
and  pathologic  conditions  such  as  endometeriosis,  dysfunc-
tional uterine bleeding, and endometrial cancer (58). Recent-
ly, a study assessed miRNA expression by microarray analysis 
in paired ectopic and eutopic endometrial tissues (70). They 
identified 14 up-regulated (miR-145, miR-143, miR-99a, miR- MicroRNAs in Lung, Liver and Kidney Diseases and Infectious Diseases
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99b,  miR-126,  miR-100,  miR-125b,  miR-150,  miR-125a,  miR- 
223,  miR-194,  miR-365,  miR-29c ,  a n d  m i R - 1 )  a n d  8  d o w n -  
regulated  (miR-  200a,  miR-141,  miR-200b,  miR-142-3p, 
miR-424, miR-34c, miR-20a and miR-196b). In addition, func-
tional analysis suggested that the 673 miRNA targets constitute 
molecular pathways previously associated with endometriosis, 
including c-Jun, CREB-binding protein, protein kinase B (Akt), 
and cyclin D1 (CCND1) signaling (70). Accordingly, miRNAs 
are  potential  therapeutic  targets  for  treating  this  disease.
CONCLUSION
Emerging evidence has demonstrated that miRNAs play a ma-
jor role in a wide range of developmental process including 
cell proliferation, cell cycle, cell differentiation, metabolism, 
apoptosis, developmental timing, neuronal cell fate, neuronal 
gene expression, brain morphogenesis, muscle differentiation 
and stem cell division. Recent studies provided clear evidence 
that miRNAs are abundant in the lung, liver and kidney and 
modulate a diverse spectrum of their functions. Moreover, a 
large  number  of  studies  have  reported  links  between  alter-
ations  of  miRNA  homeostasis  and  pathological  conditions 
such as infectious diseases, sickle cell disease and endome-
trium  diseases  as  well  as  lung,  liver  and  kidney  diseases. 
Interestingly, miRNA deficiencies or excess have been corre-
lated with a number of clinically important diseases ranging 
from infectious diseases to liver diseases. Particularly, accu-
mulating  evidence  indicates  that  viruses  use  their  own 
miRNAs  to  manipulate  both  cellular  and  viral  gene  expre-
ssion. Furthermore, viral infection can exert a profound im-
pact on the host cellular miRNA expression profile, and sev-
eral RNA viruses have been reported to interact directly with 
cellular miRNAs and/or to use these miRNAs to augment their 
replication potential. It is therefore unsurprising that due to 
their non-immunogenic nature, viral miRNAs represent an ele-
gant tool for the virus to evade the host immune system and 
likely play a key role in the latent/lytic switch during the viral 
life  cycle.  Here  I  briefly  summarized  the  newly  discovered 
roles of miRNAs in various human diseases including lung, 
liver and kidney diseases as well as infectious diseases, sickle 
cell disease and enodmetrium diseases. In the future, distinct 
miRNA signature involved in diseases should define the role 
of  miRNA  in  biochemical  and  immunobiological  processes. 
Furthermore, identification of miRNAs of significance in dis-
ease  could provide rationale  for  the  design  and  implemen-
tation of disease classification, early detection, disease prog-
nosis  and  successful  therapeutic  decision  making.
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